Healthcare / Medical Instruments & SuppliesNasdaqCM
$66.93
+2.16 (+3.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $4.5M · quality 42.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
68/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$214M
P/E
18.4x
↓EV/EBITDA
17.1x
↑ROE
24.5%
↑Gross Margin
29.3%
↓Debt/Equity
0.45
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
+7.5%
FCF CAGR
—
FCF margin
-4.4%
FCF / Net income
-0.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $66.6M · net income $9.0M · FCF $-2.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $66.6M | $66.6M | $53.8M | $46.1M | $42.0M | — | — | $27.2M | $22.5M | $21.9M | $19.2M | $13.4M | $10.8M | $12.2M | $17.3M | $24.1M |
| Net Income | $9.0M | $9.0M | $2.1M | $7.1M | $4.6M | — | — | $4.1M | $1.6M | $5.1M | $822000.00 | $-365000.00 | $-488000.00 | $-1.8M | $-876000.00 | $2.6M |
| EBITDA | $14.1M | $14.1M | $4.4M | $10.8M | $6.9M | — | — | $5.4M | $2.9M | $3.3M | $1.4M | $-324000.00 | $-287000.00 | $-1.3M | $-718000.00 | $4.2M |
| EPS | 2.67 | 2.67 | 0.60 | 1.98 | 1.02 | — | — | 0.97 | 0.37 | 1.25 | 0.20 | -0.09 | — | — | -0.27 | 0.80 |
| Gross Margin | 29.3% | 29.3% | 27.0% | 27.7% | 31.2% | — | — | 36.0% | 35.4% | 32.7% | 25.6% | 27.7% | 27.4% | 30.3% | 31.4% | 42.1% |
| Operating Margin | 16.1% | 16.1% | 13.3% | 12.5% | 12.3% | — | — | 18.4% | 10.6% | 12.5% | 4.2% | -6.7% | -7.5% | -15.5% | -7.9% | 14.5% |
| Net Margin | 13.5% | 13.5% | 4.0% | 15.3% | 10.9% | — | — | 15.3% | 7.2% | 23.2% | 4.3% | -2.7% | -4.5% | -14.6% | -5.1% | 11.0% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.45 | 0.45 | 0.44 | 0.47 | 0.63 | — | — | 0.27 | — | — | — | — | — | — | 0.04 | 0.12 |
| Current Ratio | 3.67 | 3.67 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-2.9M | $-2.9M | $5.2M | $4.5M | $-2.5M | — | — | $1.9M | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||
| ROE | 24.5% | 24.5% | 6.9% | 22.4% | 18.0% | — | — | 24.4% | 9.4% | 37.1% | 9.3% | -4.3% | -5.3% | -22.5% | -9.2% | 25.6% |
| Valuation | ||||||||||||||||
| P/E | 18.44 | 18.44 | 29.30 | 9.25 | 15.67 | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 17.07 | 17.07 | 16.83 | 7.26 | 10.93 | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 6.14 | 6.14 | 2.02 | 2.11 | 2.36 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | 23.7% | 23.7% | 16.8% | 9.6% | — | — | — | 21.0% | 2.4% | 14.4% | 43.4% | 23.8% | -11.7% | -29.0% | -28.3% | — |
| EPS Growth | 348.5% | 348.5% | -69.9% | 94.1% | — | — | — | 162.2% | -70.4% | 525.0% | 322.2% | — | — | — | -133.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
30.5%
EPS terminal req.
$5.94
Spread vs growth
317.9%
5Y implied EPS CAGR
21.9%
EPS terminal req.
$7.19
Spread vs growth
326.6%
10Y implied EPS CAGR
15.8%
EPS terminal req.
$11.57
Spread vs growth
332.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+67.1%
Start / end P/E
67.2x → 25.1x
EPS bridge
0.60 → 2.67
Residual
-218.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.